Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal HAYATI Journal of Biosciences JURNAL BIOLOGI INDONESIA Berita Biologi
Sari, Isti Kartika
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Earth & Planetary Sciences

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
IDENTIFIKASI MOLEKULER VIRUS PAPILLOMA GENITAL PADA DUA SPESIES PRIMATA DI FASILITAS PENANGKARAN PUSAT STUDI SATWA PRIMATA-INSTITUT PERTANIAN BOGOR Sari, Isti Kartika; Suparto, Irma H; Iskandriati, Diah
JURNAL BIOLOGI INDONESIA Vol 10, No 1 (2014): JURNAL BIOLOGI INDONESIA
Publisher : Perhimpunan Biologi Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14203/jbi.v10i1.339

Abstract

Tulisan Pendek
PENAPISAN MODEL HEWAN PRIMATA Macaca fascicularis UNTUK UJI VAKSIN Human Papilloma Virus Sari, Isti Kartika; Mariya, Silmi; Setyawaty, Dyah; Suparto, Irma H.; Mustopa, Apon Z.; Darusman, Huda Salahudin
Berita Biologi Vol 23 No 2 (2024): Berita Biologi
Publisher : BRIN Publishing (Penerbit BRIN)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55981/beritabiologi.2024.1052

Abstract

Pemanfaatan hewan primata dalam hal ini monyet ekor panjang (MEP) atau Macaca fascicularis sebagai hewan model untuk uji vaksin Human Papilloma Virus (HPV) harus melalui penapisan untuk mendapatkan hewan yang tepat. Tujuan dari penelitian ini untuk menapis dan memvalidasi kecocokan MEP sebagai hewan model vaksin papillomavirus. Jenis vaksin yang akan di uji menentukan jenis penapisan yang dilakukan. Metode penapisan dilakukan dengan uji serologis, molecular dan patologi serta validasi dengan histopatologi. Vaksin pencegahan atau profilaksis memerlukan hewan yang bebas dari virus-virus penekan kekebalan tubuh (immunosuppressive virus) dan HPV nya sendiri agar antibodi yang terbentuk benar-benar berasal dari vaksin yang diujikan, vaksin terapeutik memilih hewan dengan positif MfPV khususnya MfPV3. Hasil penapisan dari 136 ekor hewan diperoleh 42 (30%) ekor hewan dengan negatif antibodi serta  diperoleh  39 (28%) ekor MEP positif MfPV diantaranya yaitu sebanyak 24 (17%) ekor positif MfPV-3. Hewan dengan positif MfPV3 selanjutnya akan digunakan untuk uji vaksin terapeutik HPV. Adanya perubahan abnormal sel-sel epitel serviks pada hewan dengan positif MfPV yang menuju pada pembentukkan sel kanker (Carcinoma Intra epithelial Neoplasia/CIN) juga semakin menguatkan kemiripan model MEP dengan manusia.
Preclinical Evaluation of HPV Type 52 L1L2 Chimeric Protein as a Cervical Cancer Vaccine Candidate Sari, Isti Kartika; Pamungkas, Joko; Mustopa, Apon Zaenal; Wibawan, I Wayan Teguh; Mamangkey, Jendri; Chairunnisa, Sheila; Irawan, Herman; Hertati, Ai; Ekawati, Nurlaili; Umami, Rifqiyah Nur; Novianti, Ela; Nurfatwa, Maritsa; Darusman, Huda Shalahudin
HAYATI Journal of Biosciences Vol. 33 No. 3 (2026): May 2026
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.33.3.556-565

Abstract

High-risk human papillomaviruses (HPVs) are the primary etiological agents of cervical cancer, accounting for more than 300,000 deaths annually worldwide. Current prophylactic vaccines based on recombinant L1 major capsid virus-like particles (VLPs) have demonstrated strong efficacy but are restricted to a limited spectrum of HPV types. To address this limitation, the present study evaluated a recombinant L1L2 chimeric protein derived from HPV type 52 as a potential candidate for a broad-spectrum vaccine. The chimeric protein was expressed in Escherichia coli strain BL21 (DE3) and purified for immunization studies. Female BALB/c mice (Mus musculus, n = 5 groups) were immunized, and immune responses were analyzed by enzyme-linked immunosorbent assay (ELISA) and pseudovirion-based neutralization assays (PBNA). The recombinant L1L2 vaccine candidate induced detectable antibody responses against HPV antigens; however, neutralizing activity remained modest. Histopathological analysis of liver and kidney tissues showed no evidence of toxicity, supporting the safety profile of the candidate. In summary, these results suggest that the HPV type 52 L1L2 chimeric protein represents a promising platform for the development of cervical cancer vaccines, although further optimization is required to achieve robust cross-neutralizing efficacy.
Co-Authors Ai Hertati, Ai Apon Zaenal Mustopa Chairunnisa, Sheila DIAH ISKANDRIATI Ekawati, Nurlaili Huda Shalahudin Darusman I wayan Teguh Wibawan Irawan, Herman Jendri Mamangkey Joko Pamungkas Mustopa, Apon Z. Novianti, Ela Nurfatwa, Maritsa Rifqiyah Nur Umami, Rifqiyah Nur Setyawaty, Dyah SILMI MARIYA Suparto, Irma H Suparto, Irma H.